Convective washout reduces the antidiarrheal efficacy of enterocyte surface-targeted antisecretory drugs

Journal of General Physiology

Volumn 141, Issue 2, 2013, Pages 261-272

  Jin, Byung Ju ^a,b   Thiagarajah, Jay R ^a,b,c   Verkman, A S ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84874743961     PISSN: 00221295     EISSN: 15407748     Source Type: Journal    
DOI: 10.1085/jgp.201210885     Document Type: Article

References (29)

1. Al-Awqati, Q. 2002. Alternative treatment for secretory diarrhea revealed in a new class of CFTR inhibitors. J. Clin. Invest. 110: 1599-1601.
2. Banwell, J.G., N.F. Pierce, R.C. Mitra, K.L. Brigham, G.J. Caranasos, R.I. Keimowitz, D.S. Fedson, J. Thomas, S.L. Gorbach, R.B. Sack, and A. Mondal. 1970. Intestinal fluid and electrolyte transport in human cholera. J. Clin. Invest. 49:183-195. http://dx.doi.org/10.1172/JCI106217.
3. Bearcroft, C.P., E.A. André, and M.J. Farthing. 1997. In vivo effects of the 5-HT3 antagonist alosetron on basal and cholera toxininduced secretion in the human jejunum: a segmental perfusion study. Aliment. Pharmacol. Ther. 11:1109-1114. http://dx.doi.org/10.1046/j.1365-2036.1997.d01-1389.x.
4. - channel by heat-stable enterotoxin and guanylin via cAMP-dependent protein kinase. EMBO J. 13:1065-1072.
5. Charmot, D. 2012. Non-systemic drugs: a critical review. Curr. Pharm. Des. 18:1434-1445.
6. Cottreau, J., A. Tucker, R. Crutchley, and K.W. Garey. 2012. Crofelemer for the treatment of secretory diarrhea. Expert Rev. Gastroenterol. Hepatol. 6:17-23. http://dx.doi.org/10.1586/egh.11.87.
7. de Hostos, E.L., R.K. Choy, and T. Nguyen. 2011. Developing novel antisecretory drugs to treat infectious diarrhea. Future Med Chem. 3:1317-1325. http://dx.doi.org/10.4155/fmc.11.87.
8. Field, M. 1979. Mechanisms of action of cholera and Escherichia coli enterotoxins. Am. J. Clin. Nutr. 32:189-196.
9. Gabriel, S.E., K.N. Brigman, B.H. Koller, R.C. Boucher, and M.J. Stutts. 1994. Cystic fibrosis heterozygote resistance to cholera toxin in the cystic fibrosis mouse model. Science. 266:107-109. http://dx.doi.org/10.1126/science.7524148.
10. Jakab, R.L., A.M. Collaco, and N.A. Ameen. 2011. Physiological relevance of cell-specific distribution patterns of CFTR, NKCC1, NBCe1, and NHE3 along the crypt-villus axis in the intestine. Am.J. Physiol. Gastrointest. Liver Physiol. 300:G82-G98. http://dx.doi.org/10.1152/ajpgi.00245.2010.
11. Loehry, C.A., and B. Creamer. 1969. Three-dimensional structure of the human small intestinal mucosa in health and disease. Gut. 10:6-12. http://dx.doi.org/10.1136/gut.10.1.6.
12. Marsh, M.N., and J.A. Swift. 1969. A study of the small intestinal mucosa using the scanning electron microscope. Gut. 10:940-949. http://dx.doi.org/10.1136/gut.10.11.940.
13. Muanprasat, C., N.D. Sonawane, D. Salinas, A. Taddei, L.J. Galietta, and A.S. Verkman. 2004. Discovery of glycine hydrazide poreoccluding CFTR inhibitors: Mechanism, structure-activity analysis, and in vivo efficacy. J. Gen. Physiol. 124:125-137. http://dx.doi.org/10.1085/jgp.200409059.
14. Murek, M., S. Kopic, and J. Geibel. 2010. Evidence for intestinal chloride secretion. Exp. Physiol. 95:471-478. http://dx.doi.org/10.1113/expphysiol.2009.049445.
15. Naftalin, R.J., P.S. Zammit, and K.C. Pedley. 1995. Concentration polarization of fluorescent dyes in rat descending colonic crypts: evidence of crypt fluid absorption. J. Physiol. 487:479-495.
16. Snyder, D.S., L. Tradtrantip, C. Yao, M.J. Kurth, and A.S. Verkman. 2011. Potent, metabolically stable benzopyrimido-pyrrolo-oxazinedione (BPO) CFTR inhibitors for polycystic kidney disease. J. Med. Chem. 54:5468-5477. http://dx.doi.org/10.1021/jm200505e.
17. Sonawane, N.D., J. Hu, C. Muanprasat, and A.S. Verkman. 2006. Luminally active, nonabsorbable CFTR inhibitors as potential therapy to reduce intestinal fluid loss in cholera. FASEB J. 20: 130-132.
18. Sonawane, N.D., D. Zhao, O. Zegarra-Moran, L.J. Galietta, and A.S. Verkman. 2007. Lectin conjugates as potent, nonabsorbable CFTR inhibitors for reducing intestinal fluid secretion in cholera. Gastroenterology. 132:1234-1244. http://dx.doi.org/10.1053/j.gastro.2007.02.018.
19. Sonawane, N.D., D. Zhao, O. Zegarra-Moran, L.J. Galietta, and A.S. Verkman. 2008. Nanomolar CFTR inhibition by pore-occluding divalent polyethylene glycol-malonic acid hydrazides. Chem. Biol. 15:718-728. http://dx.doi.org/10.1016/j.chembiol.2008.05.015.
20. Thiagarajah, J.R., and A.S. Verkman. 2012. CFTR inhibitors for treating diarrheal disease. Clin. Pharmacol. Ther. 92:287-290. http://dx.doi.org/10.1038/clpt.2012.114.
21. Thiagarajah, J.R., T. Broadbent, E. Hsieh, and A.S. Verkman. 2004. Prevention of toxin-induced intestinal ion and fluid secretion by a small-molecule CFTR inhibitor. Gastroenterology. 126:511-519. http://dx.doi.org/10.1053/j.gastro.2003.11.005.
22. Tradtrantip, L., N.D. Sonawane, W. Namkung, and A.S. Verkman. 2009. Nanomolar potency pyrimido-pyrrolo-quinoxalinedione CFTR inhibitor reduces cyst size in a polycystic kidney disease model. J. Med. Chem. 52:6447-6455. http://dx.doi.org/10.1021/jm9009873.
23. Tradtrantip, L., W. Namkung, and A.S. Verkman. 2010. Crofelemer, an antisecretory antidiarrheal proanthocyanidin oligomer extracted from Croton lechleri, targets two distinct intestinal chloride channels. Mol. Pharmacol. 77:69-78. http://dx.doi.org/10.1124/mol.109.061051.
24. Trbojevic-Stankovic, J.B., N.M. Milicevic, D.P. Milosevic, N. Despotovic, M. Davidovic, P. Erceg, B. Bojic, D. Bojic, P. Svorcan, M. Protic, et al. 2010. Morphometric study of healthy jejunal and ileal mucosa in adult and aged subjects. Histol. Histopathol. 25:153-158.
25. Usansky, H.H., and P.J. Sinko. 2005. Estimating human drug oral absorption kinetics from Caco-2 permeability using an absorptiondisposition model: model development and evaluation and derivation of analytical solutions for ka and Fa. J. Pharmacol. Exp. Ther. 314:391-399. http://dx.doi.org/10.1124/jpet.104.076182.
26. Van Loon, F.P., G.H. Rabbani, K. Bukhave, and J. Rask-Madsen. 1992. Indomethacin decreases jejunal fluid secretion in addition to luminal release of prostaglandin E2 in patients with acute cholera. Gut. 33:643-645. http://dx.doi.org/10.1136/gut.33.5.643.
27. Venkatasubramanian, J., M. Ao, and M.C. Rao. 2010. Ion transport in the small intestine. Curr. Opin. Gastroenterol. 26:123-128. http://dx.doi.org/10.1097/MOG.0b013e3283358a45.
28. Yang, B., N.D. Sonawane, D. Zhao, S. Somlo, and A.S. Verkman. 2008. Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease. J. Am. Soc. Nephrol. 19:1300-1310. http://dx.doi.org/10.1681/ASN.2007070828.
29. Zhang, W., N. Fujii, and A.P. Naren. 2012. Recent advances and new perspectives in targeting CFTR for therapy of cystic fibrosis and enterotoxin-induced secretory diarrheas. Future Med Chem. 4:329-345. http://dx.doi.org/10.4155/fmc.12.1.